Focus of our Strategy

The mission of Kv1.3 Therapeutics is to develop novel first in class drugs for rare autoimmune diseases that will transform patients’ lives. We have refined a process of discovering novel first in class therapies and efficiently advancing them through preclinical development to clinical proof of concept.

With dalazatide we are preparing to begin Phase 2 clinical trials in inclusion body myositis (IBM).  We believe this program is well positioned to be acquired or licensed by a larger biopharmaceutical company with an interest in rare diseases.  We believe the near term value inflection points of our lead program, may represent an attractive investment opportunity for our investors.

Kv1.3 Therapeutics is a privately held Washington corporation that seeks aligned stakeholders who share our vision of improving human health through the development of breakthrough therapies in areas of high unmet medical need. We encourage interested parties to learn more about our company and our products.

For additional information contact our Corporate Development team by sending us a message via the linked form.